Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020
November 03 2020 - 8:05AM
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or
the “Company”), a clinical-stage drug development company
pioneering transformative medicines that target the endocannabinoid
system, today announced that it will report its third quarter
financial results on Tuesday, November 10. Corbus management will
host a conference call and live audio webcast to discuss the
operational and financial results at 8:30 a.m. ET that same day.
The call will be led by Yuval Cohen, Ph.D.,
Chief Executive Officer of Corbus, who will be joined by additional
members of the Corbus management team. Interested participants and
investors may access the conference call by dialing (877) 407-3978
(domestic) or (412) 902-0039 (international). The live webcast will
be accessible on the Events page of the Investors section of the
Corbus website, www.corbuspharma.com and will be archived for 90
days Following the event.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a
clinical-stage company focused on the development and
commercialization of novel medicines designed to target the
endocannabinoid system. The Company’s lead product
candidate, lenabasum, is a novel, oral, selective cannabinoid
receptor type 2 (CB2) agonist that resolves chronic inflammation
and limits fibrosis in animal and human
models. Lenabasum is currently being evaluated in
dermatomyositis and systemic lupus erythematosus. Corbus is also
developing a pipeline of other preclinical drug candidates from its
endocannabinoid system platform.
Lenabasum is not approved for the treatment of
any indication. For more information on Corbus’ clinical programs,
please visit here.
For more information,
visit http://www.corbuspharma.com/, and connect with us
on Twitter, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's restructuring,
trial results, product development, clinical and regulatory
timelines, market opportunity, competitive position, possible or
assumed future results of operations, business strategies,
potential growth opportunities and other statements that are
predictive in nature. These forward-looking statements are based on
current expectations, estimates, forecasts and projections about
the industry and markets in which we operate and management's
current beliefs and assumptions. These statements may be
identified by the use of forward-looking expressions,
including, but not limited to, "expect," "anticipate," "intend,"
"plan," "believe," "estimate," "potential,” "predict," "project,"
"should," "would" and similar expressions and the negatives of
those terms. These statements relate to future events or our
financial performance and involve known and unknown risks,
uncertainties, and other factors, including the potential impact of
the recent COVID-19 pandemic and the potential impact of sustained
social distancing efforts, on our operations, clinical development
plans and timelines, which may cause actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Such factors include those set forth in
the Company's filings with the Securities and Exchange
Commission. Prospective investors are cautioned not to place
undue reliance on such forward-looking statements, which speak only
as of the date of this press release. The Company undertakes no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Corbus Pharmaceuticals Contacts:
Ted Jenkins, Senior Director, Investor Relations and Corporate
Communications Phone: +1 (617) 415-7745 Email:
ir@corbuspharma.com
Lindsey Smith, Director, Investor Relations and Corporate
Communications Phone: +1 (617) 415-7749 Email:
mediainfo@corbuspharma.com
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From May 2024 to Jun 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Jun 2023 to Jun 2024